Eli Lilly's Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal
Eli Lilly and Company (India) Pvt. (Lilly) and Cipla Limited have announced a strategic agreement to expand access to obesity and diabetes care in India.
Under this agreement, Cipla will distribute and promote the drug tirzepatide (Mounjaro) under a new brand name, Yurpeak. Lilly will continue to manufacture and supply the drug, while Cipla will handle marketing and distribution across India.
The price of Yurpeak will be the same as Lilly’s existing brand, Mounjaro, which was launched in India in March 2025.
No specific quotes are available in the given text.
Author's summary: Lilly and Cipla partner to expand diabetes care in India.
More News
- This ‘minor’ bird flu strain has potential to spark human pandemic
- Bank of Canada expected to cut interest rate this week as forecasters see more weakness to come for economy
- New ‘Pay One, Stay Two’ parking deal to boost Waverley town centres
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- New ‘Pay One, Stay Two’ parking deal to boost Waverley town centres
- Government shutdown threatens CPG brands tied to SNAP and WIC
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Decolonial thought in Brazilian philanthropy: Not a new label, but a new stance - Alliance magazine
- Guildford Dragon NEWS